Red cell lipid peroxidation and antioxidant system in haemodialysed patients: Influence of recombinant human erythropoietin (r-HuEPO) treatment

被引：17

作者：

Boran M. ^{[1
]}

Küçükaksu C. ^{[2
]}

Balk M. ^{[2
]}

Çetin S. ^{[1
]}

机构：

[1] Dept. Haemodialysis and Transplant., Turkiye Yuksek Ihtisas Hosp., Ankara

[2] Department of Biochemistry, Turkiye Yuksek Ihtisas Hosp., Ankara

来源：

International Urology and Nephrology | 1998年 / 30卷 / 4期

关键词：

International Urology; Decrease Lipid Peroxidation; Reduce Glutathione Content; Erythrocyte Superoxide Dismutase; Haemodialysed Patient;

D O I：

10.1007/BF02550233

中图分类号：

学科分类号：

摘要：

In order to determine the role of correcting anaemia with r-HuEPO on susceptibility of red cell to lipid peroxidation, 15 patients on maintenance haemodialysis treated with r-HuEPO for at least one year (group I), 15 patients on maintenance haemodialysis without r-HuEPO (group II) and 30 persons as a control group (group III) were included in the study. We measured etythrocyte superoxide dismutase (e-SOD), erythrocyte catalase (e- CAT) activities, plasma malonyldialdehyde (p-MDA) and serum vitamin E levels in all patients. The healthy controls (group III) had significantly lower levels of p-MDA in comparison to those measured in haemodialysed patients (groups I-II) (p<0.0001). e-SOD activity in group III was significantly higher than in groups I and II, respectively (p<0.0001 and p<0.00001), and e- SOD activity was significantly lower in group II than in group I (p<0.0001). e-CAT activity in group III was higher than in groups I and II, respectively (p<0.0001 and p<0.00001) and it was significantly lower in group II than in group I (p<0.0001). Vitamin E concentration in group III was lower than in group I and group II, respectively (p<0.0001 and p<0.0001). But there is no difference between groups I and II. This study suggests that r-HuEPO therapy improves anaemia by decreasing lipid peroxidation and increasing antioxidant activity.

引用

页码：507 / 512

页数：5

共 25 条

[11]

Schaefer, R.M., Hörl, W.H., Massry, S.G., Treatment of renal anemia with recombinant human erythropoietin (1989) Am. J. Nephrol., 9, p. 353

[12]

Yagi, K., Assay for blood plasma or serum (1984) Methods in Enzymology, 105, p. 328

[13]

Luck, H., Catalase (1965) Methods in Enzymatic Analysis, pp. 855-884. , Bergmayer, H. V. (ed.): Academic Press Inc., New York-London

[14]

Sun, Y., Oberlay, L.W., Li, Y., A simple method for clinical assay of superoxide dismutase (1988) Clin. Chem., 34, p. 497

[15]

Varley, H., Determination of serum tocopherol (1976) Practical Clinical Biochemistry. Fifth Ed., 2, pp. 222-223. , W. Heinemann Medical Books Ltd., London

[16]

Jacop, H.J., Eaton, J.W., Yawata, N.Y., Shortened red blood cell survived in uremic patients

[17]

Beneficial and deleterious effect on dialysis (1975) Kidney Int., 139, p. 143

[18]

Shainkin-Kestenbanun, R., Caniso, C., Berlyne, G.M., Reduced superoxide dismutase activity in erythrocyte of dialysis patients: A possible factor in the etiology of uremic anemia (1990) Nephron, 55, p. 251

[19]

Chakraborty, T., Ghosal, J., Bismas, T., Effect of erythropoietin on membrane lipid peroxidation, superoxide dismutase, catalase and glutathione peroxidase of rat red blood cell (1988) Biochem. Med. Metab. Biol., 40, p. 8

[20]

Pfafferott, C., Meiselmann, H.C., Hoch Stain, P., The effect of malonyldialdehyde on erythrocyte deformability (1982) Blood, 59, p. 12

← 1 2 3 →